Citations 1
A Phase 1 Study of Plamotamab, an Anti-CD20 x Anti-CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Non-Hodgkin's Lymphoma: Recommended Dose Safety/Efficacy Update and Escalation Exposure-Response Analysis
Patel, Krish , Tilly, Hervé , Ghesquières, Hervé , Collela, Jean Marc Schiano de, Chanan‐Khan, Asher , Bouabdallah, Kamal , Long, Meixiao, Clynes, Raphael , Kanodia, Jitendra , Bao, Lei , Ding, Ying , Jin, Jianhua , Ainsworth, William B., Garcha, Raman, Kye, Steve, Patel, Krish , Riedell, Peter A. , Ahmed, Sairah , Michot, Jean‐Marie , Tessoulin, Benoit , Iyengar, Sunil , Bao, Lei, Phillips, Tycel
Blood | November 28, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 9470-9472
